<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503852</url>
  </required_header>
  <id_info>
    <org_study_id>003-A-II</org_study_id>
    <nct_id>NCT02503852</nct_id>
  </id_info>
  <brief_title>STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia</brief_title>
  <acronym>STYLE</acronym>
  <official_title>Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kerastem Technologies, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kerastem Technologies, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and feasibility of the Celution
      and Puregraft Systems in the processing and preparation of an autologous fat graft enriched
      with adipose-derived regenerative cells (ADRCs) in the treatment of early alopecia
      androgenetica.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The STYLE Trial is a prospective, randomized, multi-center device trial intended to evaluate
      the safety and efficacy of the Celution and Puregraft Systems in the processing and
      preparation of an autologous fat graft enriched with adipose-derived regenerative cells
      (ADRCs) in the treatment of early alopecia androgenetica. Patients may be included if they
      are undergoing an elective cosmetic liposuction. Following informed consent and screening
      evaluations, eligible subjects will undergo pre-operative testing. Subjects will then undergo
      a fat harvest using local anesthesia with or without conscious sedating. Subjects will be
      randomly assigned to receive a fat graft cell enriched with ADRCs (available in two different
      doses),a fat graft without cell enrichment using a visually-matched blood saline solution
      (fat alone control), or a saline injection (no-fat control) in a 2:2:2:1 ratio.

      While undergoing liposuction, lipoaspirate will be processed in the Puregraft System to
      remove the lipoaspirate of impurities and in the Celution System to isolate and concentrate
      ADRCs. After the liposuction is completed), patients will have, under a ring block local
      anesthesia (see further description below), a subcutaneous scalp injection of either
      Puregraft purified autologous fat or saline (no-fat control) followed by a separate second
      injection, of either ADRCs (available in two different doses),a visually-matched blood saline
      solution (fat alone control), or saline (no-fat control) in a 2:2:2:1 ratio.

      The STYLE Clinical Trial will have a sample size of 70 patients at up to eight (8) centers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">March 2, 2018</completion_date>
  <primary_completion_date type="Actual">March 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects arm randomized prior to liposuction 2:2:2:1 ratio to one of 4 Arms. Low Dose ADR, High Dose ADRC, non enriched fat only, and no fat (control normal saline).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization via manual treatment assignment by the unblinded Clinical Supply Manager prior to the start of liposuction.
Subjects randomized into the study are assigned their study Arm corresponding to the next available number in the computer-generated randomization schedule. Dose preparation ios performed by designated unblinded qualified personnel and supplied to the blinded treating team.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; Tolerability Assessment of SAE/AE</measure>
    <time_frame>Enrollment to 52 weeks</time_frame>
    <description>Safety &amp; Tolerability of Experimental Treatment (ADRC) Assessment of SAE/AE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal (Non-Vellus) Hair Count--Change From Baseline</measure>
    <time_frame>Enrollment to 52 weeks</time_frame>
    <description>Terminal (Non-Vellus) Hair Count Assessment by Macrophotography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hair Satisfaction Questionnaire Responses at Week 24 for Questions 1 Through 4</measure>
    <time_frame>Enrollment to 24 weeks</time_frame>
    <description>Percent of positive responses, defined by increase of 1 or more from baseline, on specific written assessment of treatment outcome by Investigators scored 1-5, value 1 is lowest, value of 5 is highest, higher values represent more positive responses</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Alopecia, Androgenetic</condition>
  <arm_group>
    <arm_group_label>Fat + High Dose ADRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fat + Low Dose ADRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fat Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Fat Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Puregraft System</intervention_name>
    <description>The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.</description>
    <arm_group_label>Fat + High Dose ADRC</arm_group_label>
    <arm_group_label>Fat + Low Dose ADRC</arm_group_label>
    <arm_group_label>Fat Alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Celution System</intervention_name>
    <description>The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.</description>
    <arm_group_label>Fat + High Dose ADRC</arm_group_label>
    <arm_group_label>Fat + Low Dose ADRC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Kerastem Therapy</intervention_name>
    <description>The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.</description>
    <arm_group_label>Fat + High Dose ADRC</arm_group_label>
    <arm_group_label>Fat + Low Dose ADRC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liposuction</intervention_name>
    <description>Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
    <arm_group_label>Fat + High Dose ADRC</arm_group_label>
    <arm_group_label>Fat + Low Dose ADRC</arm_group_label>
    <arm_group_label>Fat Alone</arm_group_label>
    <arm_group_label>No Fat Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males with a diagnosis of Alopecia Androgenetica

          2. Females with a diagnosis of Alopecia Androgenetica

          3. Males with hair loss consistent with Grades III, IIIA, III-Vertex, IV, IV-A, based on
             Norwood-Hamilton Scale (Figure 1)

          4. Females with hair loss consistent with Grades I-3, I-4, II-1, II-2 based on the Savin
             Scale (Figure 2)

          5. Provide written informed consent and comply with the study requirements

          6. For women of childbearing potential: Negative pregnancy test at screening visit plus
             subject agrees to maintain two forms of contraception for the duration of the study.

          7. Subject is willing to maintain a consistent hair length and natural hair color,
             without the use of any coloring agents, during the study period.

          8. Ability to complete study procedures, patient surveys, and pictures.

          9. Subject is ≥ 18 years of age.

         10. Body Mass Index &lt; 40kg/m2

        Exclusion Criteria:

          1. Subjects who have used minoxidil, or any oral or topical medication including over the
             counter and herbal medications for the treatment of hair loss within 6 months of study
             screening, or finasteride or dutasteride within 12 months of study screening

          2. Treatment with an investigational product or procedure within 30 days or plans to
             participate in another clinical study

          3. Subject who has previously failed or has been deemed non-responsive to a previous
             experimental hair loss treatment.

          4. Subject must have no previous hair transplant, cell treatment, micro needling, or any
             other treatment in the last 6 months in the scalp.

          5. Subject is currently suffering from an active autoimmune disease such as serum lupus
             erythematosus, or alopecia areata. Subject is currently suffering from dermatologic
             condition in the treatment area or has a significant scar in the hair treatment area
             that, in the opinion of the investigator, will make hair growth difficult (such as
             systemic burns, etc.).

          6. History of autoimmune disease or organ transplantation or a patient on
             immunosuppressive medication(s).

          7. Diagnosis of cancer, receiving active treatment

          8. Active systemic infection

          9. Requires chronic antibiotics, systemic corticosteroids

         10. Use of systemic agents that increase bleeding or clotting, or disorders associated
             with these effects, including patients receiving GIIB/IIIa inhibitors within 2 weeks
             prior to the study procedure through to 1 week after the study procedure.

         11. Clinically significant medical or psychiatric illness currently or within 30 days of
             study screening as determined by the investigator

         12. Prior surgery in the treatment area

         13. Any disease or condition (medical or surgical) that, in the opinion of the
             investigator, might compromise dermatologic, hematologic, cardiovascular, pulmonary,
             renal, gastrointestinal, hepatic, or central nervous system function; or any condition
             that would place the subject at increased risk

         14. Pregnant or lactating women or women trying to become pregnant

         15. Known allergic reaction to components of study treatment and/or study injection
             procedure

         16. Subject has any disorder that may prevent compliance to study procedures and visits

         17. Subject who is part of the study staff, a family member or friend

         18. Diabetes or thyroid disorder

         19. Subject who has a sensitive, irritated, or abraded scalp area.

         20. Women who have an alternate diagnosis that is associated with hair loss.

         21. Body Mass Index &lt; 18kg/m2

         22. Clinically significant abnormal findings on laboratory screening panels, including
             hemoglobin ≤ 10 g/dL.

         23. Hepatic dysfunction, as defined as aspartate aminotransferase (AST), alanine
             aminotransferase (ALT), or bilirubin levels &gt; 1.5 times the upper limit of normal
             range (x ULN) prior to randomization.

         24. Chronic renal insufficiency as defined as a serum creatinine &gt; 1.2 mg/dL for women and
             &gt; 1.5 mg/dL for men.

         25. An elevated PT/PTT, INR, or platelet count &lt; 100 x 109/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Washenik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bosley Medical/NYU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tower Outpatient Surgery Center--Dr. Joel Aronowitz</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>920048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foundation For Hair Restoration</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgold Surgery Group</name>
      <address>
        <city>Highland Park</city>
        <state>New Jersey</state>
        <zip>08904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Festa E, Fretz J, Berry R, Schmidt B, Rodeheffer M, Horowitz M, Horsley V. Adipocyte lineage cells contribute to the skin stem cell niche to drive hair cycling. Cell. 2011 Sep 2;146(5):761-71. doi: 10.1016/j.cell.2011.07.019.</citation>
    <PMID>21884937</PMID>
  </reference>
  <reference>
    <citation>Zhu M, Zhou Z, Chen Y, Schreiber R, Ransom JT, Fraser JK, Hedrick MH, Pinkernell K, Kuo HC. Supplementation of fat grafts with adipose-derived regenerative cells improves long-term graft retention. Ann Plast Surg. 2010 Feb;64(2):222-8. doi: 10.1097/SAP.0b013e31819ae05c.</citation>
    <PMID>20098110</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <results_first_submitted>August 27, 2019</results_first_submitted>
  <results_first_submitted_qc>January 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 13, 2020</results_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Female Pattern Baldness</keyword>
  <keyword>Male Pattern Baldness</keyword>
  <keyword>Genetic Alopecia</keyword>
  <keyword>Androgenic Alopecia</keyword>
  <keyword>Hair Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 24, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT02503852/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fat + High Dose ADRC</title>
          <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
        <group group_id="P2">
          <title>Fat + Low Dose ADRC</title>
          <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
        <group group_id="P3">
          <title>Fat Alone</title>
          <description>Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
        <group group_id="P4">
          <title>No Fat Control</title>
          <description>Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects were included in the analysis population.</population>
      <group_list>
        <group group_id="B1">
          <title>Fat + High Dose ADRC</title>
          <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
        <group group_id="B2">
          <title>Fat + Low Dose ADRC</title>
          <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
        <group group_id="B3">
          <title>Fat Alone</title>
          <description>Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
        <group group_id="B4">
          <title>No Fat Control</title>
          <description>Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age(Years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.0" spread="9.1"/>
                    <measurement group_id="B2" value="43.1" spread="13.3"/>
                    <measurement group_id="B3" value="40.5" spread="12.7"/>
                    <measurement group_id="B4" value="36.1" spread="5.4"/>
                    <measurement group_id="B5" value="40.7" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety &amp; Tolerability Assessment of SAE/AE</title>
        <description>Safety &amp; Tolerability of Experimental Treatment (ADRC) Assessment of SAE/AE</description>
        <time_frame>Enrollment to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fat + High Dose ADRC</title>
            <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
          <group group_id="O2">
            <title>Fat + Low Dose ADRC</title>
            <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
          <group group_id="O3">
            <title>Fat Alone</title>
            <description>Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
          <group group_id="O4">
            <title>No Fat Control</title>
            <description>Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety &amp; Tolerability Assessment of SAE/AE</title>
          <description>Safety &amp; Tolerability of Experimental Treatment (ADRC) Assessment of SAE/AE</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Number of Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unanticipated Adverse Eventss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal (Non-Vellus) Hair Count--Change From Baseline</title>
        <description>Terminal (Non-Vellus) Hair Count Assessment by Macrophotography</description>
        <time_frame>Enrollment to 52 weeks</time_frame>
        <population>mITT, Baseline Norwood-Hamilton III</population>
        <group_list>
          <group group_id="O1">
            <title>Fat + High Dose ADRC</title>
            <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
          <group group_id="O2">
            <title>Fat + Low Dose ADRC</title>
            <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
          <group group_id="O3">
            <title>Fat Alone</title>
            <description>Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
          <group group_id="O4">
            <title>No Fat Control</title>
            <description>Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal (Non-Vellus) Hair Count--Change From Baseline</title>
          <description>Terminal (Non-Vellus) Hair Count Assessment by Macrophotography</description>
          <population>mITT, Baseline Norwood-Hamilton III</population>
          <units>Hairs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.62" spread="6.09"/>
                    <measurement group_id="O2" value="16.2" spread="4.98"/>
                    <measurement group_id="O3" value="-0.57" spread="7.53"/>
                    <measurement group_id="O4" value="-7.92" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-vellus hair count in the low-dose ADRC group in the NW3 subgroup beginning at Week 6 (mean change from baseline persisting through weeks 12 , 24, and 52.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0318</p_value>
            <p_value_desc>P value cited is the difference in non-vellus hair count between the low-dose ADRC NW3 group and the no-fat saline control at week 24</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hair Satisfaction Questionnaire Responses at Week 24 for Questions 1 Through 4</title>
        <description>Percent of positive responses, defined by increase of 1 or more from baseline, on specific written assessment of treatment outcome by Investigators scored 1-5, value 1 is lowest, value of 5 is highest, higher values represent more positive responses</description>
        <time_frame>Enrollment to 24 weeks</time_frame>
        <population>The Baseline NW3 subgroup included all male subjects with baseline Norwood Scale III, III-A and III-V.</population>
        <group_list>
          <group group_id="O1">
            <title>Fat + High Dose ADRC</title>
            <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
          <group group_id="O2">
            <title>Fat + Low Dose ADRC</title>
            <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
          <group group_id="O3">
            <title>Fat Alone</title>
            <description>Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
          <group group_id="O4">
            <title>No Fat Control</title>
            <description>Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
          </group>
        </group_list>
        <measure>
          <title>Hair Satisfaction Questionnaire Responses at Week 24 for Questions 1 Through 4</title>
          <description>Percent of positive responses, defined by increase of 1 or more from baseline, on specific written assessment of treatment outcome by Investigators scored 1-5, value 1 is lowest, value of 5 is highest, higher values represent more positive responses</description>
          <population>The Baseline NW3 subgroup included all male subjects with baseline Norwood Scale III, III-A and III-V.</population>
          <units>% of participants with + responses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="34.4"/>
                    <measurement group_id="O3" value="20.8"/>
                    <measurement group_id="O4" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Enrollment through 52 Weeks</time_frame>
      <desc>Events were reported by Investigators, which was supplemented by information from study subjects to Investigators. Attribution was performed by study Medical Director. No adverse Events were attributed to the experimental procedure / product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fat + High Dose ADRC</title>
          <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
        <group group_id="E2">
          <title>Fat + Low Dose ADRC</title>
          <description>Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Celution System: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Kerastem Therapy: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
        <group group_id="E3">
          <title>Fat Alone</title>
          <description>Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
Puregraft System: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
        <group group_id="E4">
          <title>No Fat Control</title>
          <description>Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
Liposuction: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Shilgles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hickups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Brusing or Edema</sub_title>
                <description>At liposuction or donor site, with or without pain</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eric Daniels, M.D., Chief Medical Officer</name_or_title>
      <organization>Kerastem</organization>
      <phone>858.348.8050</phone>
      <email>edaniels@puregraft.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

